Identifying the key mechanistic link(s) between loss of dystrophin and the clinical phenotype of DMD/BMD has been a major focus of research efforts with the ultimate goal of discovering new therapeutic targets to slow or prevent the dystrophic process. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.